

World Journal of *Clinical Cases*

World J Clin Cases 2023 May 16; 11(14): 3114-3368



Contents

Thrice Monthly Volume 11 Number 14 May 16, 2023

OPINION REVIEW

- 3114 Modernising autism spectrum disorder model engineering and treatment *via* CRISPR-Cas9: A gene reprogramming approach

Sandhu A, Kumar A, Rawat K, Gautam V, Sharma A, Saha L

REVIEW

- 3128 Burden of disability in type 2 diabetes mellitus and the moderating effects of physical activity

Oyewole OO, Ale AO, Ogunlana MO, Gurayah T

MINIREVIEWS

- 3140 Postoperative hypoxemia for patients undergoing Stanford type A aortic dissection

Liu HY, Zhang SP, Zhang CX, Gao QY, Liu YY, Ge SL

ORIGINAL ARTICLE

Case Control Study

- 3148 Impact of extended nursing model after multi-disciplinary treatment on young patient with post-stroke

Xu XY, Pang ZJ, Li MH, Wang K, Song J, Cao Y, Fang M

- 3158 Changes and significance of serum ubiquitin carboxyl-terminal hydrolase L1 and glial fibrillary acidic protein in patients with glioma

Zhu QH, Wu JK, Hou GL

Retrospective Study

- 3167 Multitrack and multianchor point screw technique combined with the Wiltse approach for lesion debridement for lumbar tuberculosis

Yuan YF, Ren ZX, Zhang C, Li GJ, Liu BZ, Li XD, Miao J, Li JF

- 3176 Clinical features and prognostic factors in 49 patients with follicular lymphoma at a single center: A retrospective analysis

Wu H, Sun HC, Ouyang GF

- 3187 Value of optical coherence tomography measurement of macular thickness and optic disc parameters for glaucoma screening in patients with high myopia

Mu H, Li RS, Yin Z, Feng ZL

Observational Study

- 3195 Comparative study of the clinical efficacy of all-inside and traditional techniques in anterior cruciate ligament reconstruction

An BJ, Wang YT, Zhao Z, Wang MX, Xing GY

- 3204** Positioning and design by computed tomography imaging in neuroendoscopic surgery of patients with chronic subdural hematoma

Wang XJ, Yin YH, Zhang LY, Wang ZF, Sun C, Cui ZM

- 3211** Evaluation of chronic idiopathic tinnitus and its psychosocial triggers

Hamed SA, Attiah FA, Fawzy M, Azzam M

- 3224** Intestinal complications in patients with Crohn's disease in the Brazilian public healthcare system between 2011 and 2020

Sasaki LY, Martins AL, Galhardi-Gasparini R, Saad-Hossne R, Ritter AMV, Barreto TB, Marcolino T, Balula B, Yang-Santos C

Randomized Controlled Trial

- 3238** Effect of non-pharmacological treatment on the full recovery of social functioning in patients with attention deficit hyperactivity disorder

Lv YB, Cheng W, Wang MH, Wang XM, Hu YL, Lv LQ

CASE REPORT

- 3248** Diagnosis of tuberculous uveitis by the macrogenome of intraocular fluid: A case report and review of the literature

Zhang YK, Guan Y, Zhao J, Wang LF

- 3256** Intragastric fish bones migrate into the liver: A case report

Dai MG, Zheng JJ, Yang J, Ye B

- 3261** Primary seminal vesicle adenocarcinoma with a history of seminal vesicle cyst: A case report and review of literature

Yao Y, Liu S, He YL, Luo L, Zhang GM

- 3267** Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn's disease: A case report

Gao MJ, Xu Y, Wang WB

- 3275** Late-onset mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome with mitochondrial DNA 3243A>G mutation masquerading as autoimmune encephalitis: A case report

Wang JW, Yuan XB, Chen HF

- 3282** Metastatic gastric cancer from breast carcinoma presenting with paraneoplastic rheumatic syndrome: A case report

Rech MB, da-Cruz ER, Salgado K, Balbinot RA, Balbinot SS, Soldera J

- 3288** Novel mutation of SPG4 gene in a Chinese family with hereditary spastic paraplegia: A case report

Wang J, Bu WT, Zhu MJ, Tang JY, Liu XM

- 3295** Chronic pulmonary mucormycosis caused by rhizopus microsporus mimics lung carcinoma in an immunocompetent adult: A case report

Guo XZ, Gong LH, Wang WX, Yang DS, Zhang BH, Zhou ZT, Yu XH

- 3304** Idiopathic sclerosing mesenteritis presenting with small bowel volvulus in a patient with antiphospholipid syndrome: A case report
Chennavasini P, Gururatsakul M
- 3311** *Neisseria mucosa* - A rare cause of peritoneal dialysis-related peritonitis: A case report
Ren JM, Zhang XY, Liu SY
- 3317** Rectal prolapse in a 30-year-old bladder stone male patient: A case report
Ding HX, Huang JG, Feng C, Tai SC
- 3323** Successful treatment of veno-arterial extracorporeal membrane oxygenation complicated with left ventricular thrombus by intravenous thrombolysis: A case report
Wang YD, Lin JF, Huang XY, Han XD
- 3330** Successful remimazolam sedation-epidural block in an older patient with severe chronic obstructive pulmonary disease: A case report
Yu JJ, Pei HS, Meng Y
- 3340** *De novo* mutation of NAXE (APOAIBP)-related early-onset progressive encephalopathy with brain edema and/or leukoencephalopathy-1: A case report
Ding L, Huang TT, Ying GH, Wang SY, Xu HF, Qian H, Rahman F, Lu XP, Guo H, Zheng G, Zhang G
- 3351** Iatrogenic atlantoaxial rotatory subluxation after thyroidectomy in a pediatric patient: A case report
Hong WJ, Lee JK, Hong JH, Han MS, Lee SS
- 3356** Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report
Jin CB, Yang L
- 3362** Primary rectal mucosa-associated lymphoid tissue lymphoma treated with only endoscopic submucosal dissection: A case report
Lee WS, Noh MG, Joo YE

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Jaw-Yuan Wang, MD, PhD, Professor, Surgical Oncologist, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. jawyuanwang@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

May 16, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report

Cai-Bao Jin, Ling Yang

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Konala VM, United States; Sehwat A, India

Received: March 2, 2023

Peer-review started: March 2, 2023

First decision: March 24, 2023

Revised: April 2, 2023

Accepted: April 7, 2023

Article in press: April 7, 2023

Published online: May 16, 2023



Cai-Bao Jin, Ling Yang, Department of Thoracic Oncology, Hubei Cancer Hospital, Wuhan 430000, Hubei Province, China

Corresponding author: Ling Yang, MD, Chief Doctor, Department of Thoracic Oncology, Hubei Cancer Hospital, No. 116 Zhuodaoquan South Road, Wuhan 430000, Hubei province, China. 348711624@qq.com

Abstract

BACKGROUND

Bladder metastasis from lung cancer with epidermal growth factor receptor (EGFR) mutation is extremely rare. Here, we report a case of bladder metastasis from lung adenocarcinoma with EGFR mutation.

CASE SUMMARY

A 53-year-old female patient was diagnosed with advanced lung adenocarcinoma with EGFR exon 19 deletion. Multiple nodules on the bladder wall were found by regular examination of the pelvic cavity through computed tomography during targeted therapy. Further cystoscopy and histological examination of bladder biopsy tissues confirmed the bladder metastasis from lung adenocarcinoma. In addition, genetic analysis of the bladder metastasis revealed EGFR T790M mutation. The patient achieved a good response to a third-generation EGFR tyrosine kinase inhibitor.

CONCLUSION

During routine follow-up of lung cancer patients, imaging examination of the pelvic cavity should be performed to avoid missing bladder metastasis. The ultimate diagnosis of bladder metastasis still depends on the pathological result of biopsy tissues.

Key Words: Bladder metastasis; Lung cancer; EGFR mutation; Tyrosine kinase inhibitor; Histological examination; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Bladder metastasis from lung cancer with epidermal growth factor receptor (EGFR) mutation is extremely rare. We reported a case of bladder metastasis from lung adenocarcinoma with EGFR mutation. During routine follow-up of lung cancer patients, imaging examination of the pelvic cavity should be performed to avoid missing bladder metastasis. The ultimate diagnosis of bladder metastasis still depends on the pathological result of biopsy tissues as determined by cystoscopy. Bladder metastasis with EGFR mutation seems to respond well to the treatment of EGFR tyrosine kinase inhibitors.

Citation: Jin CB, Yang L. Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report. *World J Clin Cases* 2023; 11(14): 3356-3361

URL: <https://www.wjgnet.com/2307-8960/full/v11/i14/3356.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i14.3356>

INTRODUCTION

Bladder cancer is one of the most common urinary carcinomas, only a small percentage of which are metastases from a distant primary cancer. Previous studies have shown that the primary tumors with bladder metastases could originate from stomach, melanoma, breast and lung[1]. In addition, lung cancer with bladder metastasis is especially rare. Here, we described a case of bladder metastasis from lung adenocarcinoma that was found during targeted therapy by accident. In particular, genetic analysis of the bladder metastasis tissue showed epidermal growth factor receptor (EGFR) exon 19 deletion and exon 20 T790M mutation.

CASE PRESENTATION

Chief complaints

A lung cancer patient returned to the hospital for re-examination with a complaint of significant loss of appetite during targeted therapy.

History of present illness

Significant loss of appetite started one month before the patient's return to the hospital.

History of past illness

In April 2019, a 53-year-old woman went to the hospital with pain in the left leg and was found to have a pulmonary nodule. Positron Emission Tomography-Computed Tomography showed a solid mass in the upper lobe of the left lung, multiple small nodules in the bilateral lungs and bone destruction in the left ischium and femur. Brain magnetic resonance imaging revealed multiple nodules in the left temporal lobe and cerebellum. The pathological diagnosis based on the left lung mass biopsy sample was adenocarcinoma. Genetic analysis of the biopsy tissue revealed EGFR exon 19 deletion. The first-generation EGFR tyrosine kinase inhibitor icotinib was administered. The patient achieved stable disease, but clinical symptoms did not improve significantly. A chemotherapy regimen (pemetrexed) was administered for two cycles simultaneously during targeted therapy in July 2019. Until January 2022, the patient continued to show significant loss of appetite.

Personal and family history

The patient denied any family history of malignant tumors.

Physical examination

Her vital signs were as follows: Body temperature, 36.6°C; blood pressure, 120/80 mmHg; heart rate, 85 beats per min; respiratory rate, 20 breaths per min. Furthermore, there was no positive signs related to the disease.

Laboratory examinations

Levels of serum tumor markers were as follows: Carcinoembryonic antigen, 263 ng/mL; carbohydrate antigen 125, 64.5 U/mL; squamous cell carcinoma antigen, 0.99 ng/mL. No abnormality was found in routine blood and urine analyses.

Imaging examinations

Examination of the chest, abdomen and pelvic cavity through computed tomography revealed multiple




Figure 1 Computed tomography images recorded tumor regression of bladder metastasis after almonertinib therapy. A-C: Before treatment; D-F: After treatment.

nodules on the bladder wall (Figure 1). The lesions of the lung and brain were stable.

FINAL DIAGNOSIS

To determine the origin of the nodules on the bladder wall, cystoscopic examination was subsequently performed. The cystoscopy analysis revealed multiple solid lesions on the anterior and bottom walls of the bladder (Figure 2). Bladder lesion biopsy was performed, and histological examination showed that the sample was a bladder metastasis derived from lung adenocarcinoma. Immunohistochemistry analysis showed positive staining for TTF-1 and CK7 and negative staining for P40 and GATA3 (Figure 3). Furthermore, genetic analysis of the mass biopsy showed EGFR exon 19 deletion and exon 20 T790M mutation.

Given the above findings combined with the patient's medical history, the final diagnosis was bladder metastasis derived from lung adenocarcinoma with EGFR exon 19 deletion and exon 20 T790M mutation.

TREATMENT

In February 2022, the patient began to receive targeted therapy with the third-generation EGFR tyrosine kinase inhibitor almonertinib and achieved a partial response.

OUTCOME AND FOLLOW-UP

One year after the treatment with almonertinib, the patient had sustained partial remission. There were no obvious adverse events.

DISCUSSION

Lung cancer is the most common cancer in males worldwide and the most frequent cause of cancer-related death. The main hematogenous metastatic sites for lung cancer are the bone, brain, liver, and adrenal glands. Metastasis in the bladder, which is an uncommon distant metastatic site, has been reported in only a few cases thus far. According to the timing of occurrence, bladder metastasis can be divided into two types: synchronous and metachronous metastasis. Synchronous bladder metastasis is mostly found during examinations of the primary site. For the metachronous type, the mean time from the diagnosis of lung cancer to the occurrence of bladder metastasis is one year[2]. In our case, bladder metastasis occurred thirty-three months after the initial diagnosis of lung cancer.




Figure 2 Cystoscopy analysis revealed multiple solid lesions on the anterior and bottom walls of the bladder. A: Solid lesion on the anterior wall; B and C: Solid lesion on the bottom wall.




Figure 3 Histopathological findings in metastatic bladder sample. A: Hematoxylin and eosin stained sections; B Negative staining for GATA3; C: Negative staining for P40; D: Positive staining for thyroid transcription factor 1.

For primary bladder cancer, a common clinical manifestation is macroscopic hematuria at diagnosis. Macroscopic hematuria is also a late-stage manifestation of bladder metastasis, as malignant cells must infiltrate the bladder lining. In addition to hematuria, hydronephrosis is another common symptom that can present in combination with hematuria. In addition, other symptoms, such as pelvic pain and dysuria, can also suggest the possibility of bladder metastasis of lung cancers. In our case, the patient had no typical symptoms related to bladder metastasis. However, left hydronephrosis was seen on imaging examination, which disappeared after effective targeted therapy.

During routine follow up of lung cancer patients, the examination of the pelvic cavity through computed tomography or magnetic resonance imaging should be performed to avoid overlooking bladder metastasis. The definite diagnosis is based on pathological examination of the bladder biopsy tissues.

Cystoscopy plays an important role in the diagnosis of bladder tumors. Some studies have indicated that bladder metastasis is likely to be isolated, while primary bladder tumors are frequently found in multiples. In our case, multiple lesions were found on cystoscopy. According to the previous cases, a common location of bladder metastasis is the lateral walls of the bladder[2]. Because of the route of blood circulation, bladder metastases are usually located in the lamina propria or muscularis propria of the bladder wall, while primary bladder tumors often originate from the mucosa. In our case, multiple bladder metastases were found on the anterior and bottom walls of the bladder.

Primary bladder cancer cases mostly include urothelial carcinoma. According to previously reported cases, the most common pathological type of bladder metastasis from lung cancer is adenocarcinoma [2]. Confirmed diagnosis of bladder tumors depends on immunohistochemistry analysis of biopsy tissues. In our case, the immunohistochemistry analysis showed positive staining for TTF-1 and CK7 and negative staining for P40 and GATA3. The marker CK-7 represents epithelial origin and thus cannot distinguish between lung and bladder cells. The marker GATA3 suggests urothelial differentiation and thus helped eliminate the possibility of urothelial origin. The positive TTF-1 staining suggested that the primary lung adenocarcinoma was the origin with high sensitivity and specificity. Therefore, we confirmed the diagnosis of bladder metastasis from lung cancer by combined analysis of these markers.

In previously published case reports, there were only two cases mentioning the gene mutation status of the lung cancer [3,4]. Both lung cancer patients with bladder metastasis had sensitive EGFR mutations and lacked the T790M mutation before and after the treatment with targeted therapy or chemotherapy. However, in our case, the T790M mutation was detected using bladder biopsy tissue after the progression on first-line targeted therapy. Moreover, the bladder metastasis responded well to targeted therapy with third-generation EGFR tyrosine kinase inhibitors. Due to the limited reported cases and available information, no correlation between the clinical characteristics of lung cancer patients and the occurrence of bladder metastasis has been found until now.

CONCLUSION

Bladder metastasis from lung cancer with EGFR mutation is extremely rare. During routine follow-up of lung cancer patients, imaging examination of the pelvic cavity should be performed to avoid missing bladder metastasis. The ultimate diagnosis of bladder metastasis still depends on the pathological result of biopsy tissues as determined by cystoscopy. Bladder metastasis with EGFR mutation seems to respond well to the treatment of EGFR tyrosine kinase inhibitors.

FOOTNOTES

Author contributions: Jin CB performed the research and wrote the paper; Yang L supervised the report.

Informed consent statement: Patient was not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after patient agreed to treatment by written consent.

Conflict-of-interest statement: We have no financial relationships to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Cai-Bao Jin 0000-0003-3544-5774; Ling Yang 0000-0002-5914-9614.

S-Editor: Ma YJ

L-Editor: A

P-Editor: Yuan YY

REFERENCES

- 1 Zaghbib S, Chakroun M, Saadi A, Boussaffa H, Znaidi N, Rammeh S, Ayed H, Chebil M. Isolated bladder metastasis from lung adenocarcinoma: a case report. *J Surg Case Rep* 2021; rjab195 [PMID: 34055288 DOI: 10.1093/jscr/rjab195]
- 2 Sanguedolce F, Loizzi D, Sollitto F, Di Bisceglie M, Lucarelli G, Carrieri G, Bufo P, Cormio L. Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. *Oncology* 2017; 92: 125-134 [PMID: 28056456 DOI: 10.1159/000454731]
- 3 Li X, Zhang L, Zeng L, Wang X, Song W, Zhong D. Difficult differential diagnosis of bladder pedicled masses about metastasis from non-small cell lung cancer: A case report. *Cancer Biol Ther* 2021; 22: 106-111 [PMID: 33612067 DOI: 10.1080/15384047.2020.1840885]

- 4 **Kuga T**, Machida K, Ito H, Matsuo M. Bilateral Hydronephrotic Bladder Metastasis from Lung Cancer. *Intern Med* 2018; **57**: 1801 [PMID: [29434150](#) DOI: [10.2169/internalmedicine.9535-17](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

